How we can hijack the media, in four easy lessons
Love it, hate it, good story, bad story... the media are going to keep reporting on ME/CFS no matter what. But isn’t it time that we saw that coverage as an opportunity?
Discuss the article on the Forums.

Prof Jonathon Edwards to be IiME Rituximab trial advisor

Discussion in 'General ME/CFS News' started by Sasha, Jul 14, 2013.

  1. Sasha

    Sasha Fine, thank you

    Messages:
    14,455
    Likes:
    30,243
    UK
    Bob, Esther12, Sean and 4 others like this.
  2. Purple

    Purple Bundle of purpliness

    Messages:
    1,436
    Likes:
    2,486
    EXCELLENT NEWS!
    (yes, I did mean to shout this...)
     
    SOC, Dolphin, sproggle and 1 other person like this.
  3. user9876

    user9876 Senior Member

    Messages:
    1,545
    Likes:
    7,275
    sproggle, SOC, Esther12 and 2 others like this.
  4. Esther12

    Esther12 Senior Member

    Messages:
    6,850
    Likes:
    15,811
    Good news.

    Hopefully he might be able to advance work on finding a way of identifying those patients most likely to benefit. Linking the rituximab CFS work to others working in a similar area but outside of CFS seems like a really positive move.
     
    Sasha and Valentijn like this.
  5. Gemini

    Gemini Senior Member

    Messages:
    529
    Likes:
    650
    Esther,

    You're absolutely right!

    In RA they can identify non-responders to rituximab using an interferon [gene expression] signature:

    "The interferon type I signature towards prediction of non-response to rituximab in rheumatoid arthritis patients, " Arthritis Res Ther, April 2012

    http://www.ncbi.nlm.nih.gov/pubmed/22540992

    Let's hope the Professor is familiar with this groundbreaking work in another disease & can apply it to ME/CFS.
     
    Sasha and Valentijn like this.

See more popular forum discussions.

Share This Page